Inovio August volatility elevated into expected data release Inovio July call option implied volatility is at 121, August is 198, November is at 138; compared to its 3-monrh average of 135 according to Track Data. Elevated volatility suggests large price movement into the expected data release for a cervical cancer vaccine study.
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Inovio's VGX-3100 for cervical dysplasia shows positive Phase II results Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.